<DOC>
	<DOCNO>NCT00264953</DOCNO>
	<brief_summary>This study design ( 1 ) compare efficacy BEACOPP regimen ABVD 4-cycle chemotherapy combine involved field irradiation ( 2 ) define optimum radiation dose compare 30 20 Gy context .</brief_summary>
	<brief_title>HD11 Intermediate Stages</brief_title>
	<detailed_description />
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Bleomycin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Procarbazine</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<criteria>Hodgkin´s lymphoma ( histologically proven ) CS ( PS ) IA , IB , IIA , one risk factor ad CS ( PS ) IIB risk factor c 1. bulky mediastinal mass ( &gt; 1/3 maximum transverse thorax diameter ) 2. extranodal involvement 3 . ESR &gt; 50 ( A ) , &gt; 30 ( Bsymptoms ) 4 . 3 lymph node area involve write informaed consent Leukocytes &lt; 3000/microl Platelets &lt; 100000/microl Hodgkin´s Disease `` composite lymphoma '' Activity index ( WHO ) &lt; grade 2</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>Hodgkin´s lymphoma</keyword>
	<keyword>intermediate stage</keyword>
</DOC>